QuidelOrtho (NASDAQ:QDEL) Issues FY 2026 Earnings Guidance

Posted by on May 5th, 2026

QuidelOrtho (NASDAQ:QDEL – Get Free Report) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 1.800-2.000 for the period, compared to the consensus EPS estimate of 2.170. The company issued revenue guidance of $2.7 billion-$2.8 billion, compared to the consensus revenue estimate of $2.7 billion.

QuidelOrtho Trading Down 6.1%

QDEL stock traded down $0.76 during trading on Tuesday, reaching $11.66. The company had a trading volume of 3,184,109 shares, compared to its average volume of 2,822,970. QuidelOrtho has a 52 week low of $10.86 and a 52 week high of $38.99. The company has a market cap of $794.05 million, a P/E ratio of -0.70 and a beta of 0.75. The business has a 50 day moving average of $16.58 and a 200 day moving average of $23.82. The company has a debt-to-equity ratio of 1.29, a current ratio of 1.50 and a quick ratio of 0.90.

QuidelOrtho (NASDAQ:QDEL – Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). QuidelOrtho had a negative net margin of 41.46% and a positive return on equity of 5.91%. During the same quarter in the prior year, the firm posted $0.74 EPS. The company’s revenue was down 10.5% on a year-over-year basis. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. As a group, sell-side analysts forecast that QuidelOrtho will post 2.18 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on QDEL shares. Wall Street Zen downgraded shares of QuidelOrtho from a “buy” rating to a “hold” rating in a research note on Sunday, April 12th. UBS Group decreased their target price on shares of QuidelOrtho from $30.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, April 10th. Citigroup raised their price objective on QuidelOrtho from $23.00 to $30.00 and gave the company a “neutral” rating in a research report on Thursday, February 12th. Zacks Research lowered QuidelOrtho from a “hold” rating to a “strong sell” rating in a research report on Tuesday, February 17th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average price target of $28.25.

View Our Latest Report on QDEL

Insider Activity at QuidelOrtho

In other news, CFO Joseph M. Busky purchased 3,370 shares of QuidelOrtho stock in a transaction that occurred on Friday, February 13th. The stock was bought at an average price of $23.66 per share, with a total value of $79,734.20. Following the completion of the transaction, the chief financial officer directly owned 10,290 shares of the company’s stock, valued at approximately $243,461.40. The trade was a 48.70% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Brian J. Blaser purchased 10,540 shares of QuidelOrtho stock in a transaction that occurred on Friday, February 13th. The shares were purchased at an average cost of $23.59 per share, with a total value of $248,638.60. Following the transaction, the chief executive officer directly owned 40,073 shares of the company’s stock, valued at $945,322.07. This represents a 35.69% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought 23,910 shares of company stock valued at $567,973 over the last 90 days. Corporate insiders own 0.79% of the company’s stock.

Institutional Investors Weigh In On QuidelOrtho

Institutional investors and hedge funds have recently made changes to their positions in the company. Corient Private Wealth LLC bought a new stake in QuidelOrtho in the 4th quarter worth approximately $280,000. T. Rowe Price Investment Management Inc. grew its position in QuidelOrtho by 7.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 11,832,098 shares of the company’s stock worth $337,925,000 after purchasing an additional 819,908 shares during the period. Invesco Ltd. grew its position in QuidelOrtho by 19.4% in the 4th quarter. Invesco Ltd. now owns 3,470,656 shares of the company’s stock worth $99,122,000 after purchasing an additional 563,893 shares during the period. Moore Capital Management LP bought a new stake in QuidelOrtho in the 4th quarter worth approximately $1,260,000. Finally, Balyasny Asset Management L.P. bought a new stake in QuidelOrtho in the 4th quarter worth approximately $9,953,000. Institutional investors own 99.00% of the company’s stock.

QuidelOrtho Company Profile

(Get Free Report)

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.

Read More

Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with MarketBeat.com's FREE daily email newsletter.